FDG-PET as an independent biomarker for Alzheimer’s biological diagnosis: a longitudinal study
Open accessThe DOI matches its Crossref record; 49 of the 50 references it cites were found in a registry or an index.
Abstract
BACKGROUND: F-fluorodeoxyglucose-positron emission tomography (FDG-PET) brain metabolism was recognized as a biomarker of neurodegeneration in the recently proposed ATN framework for Alzheimer's disease (AD) biological definition. However, accumulating evidence suggested it is an independent biomarker, which is denoted as "F" in the very study. METHODS: A total of 551 A+T+ individuals from the Alzheimer's Disease Neuroimaging Initiative database were recruited and then further divided into four groups based on the biomarker positivity as 132 A+T+N-F-, 102 A+T+N-F+, 113 A+T+N+F-, and 204 A+T+N+F+. Frequency distributions of the groups were compared, as well as the clinical progression [measured by the longitudinal changes in cognition and brain structure, and mild cognitive impairment (MCI) to AD dementia conversion] between every pair of F+ and F- groups. RESULTS: The prevalence of A+T+N+F+ profile was 66.24% in clinically diagnosed AD dementia patients; similarly, the majority of individuals with reduced FDG-PET were AD dementia subjects. Among the 551 individuals that included, 537 had at least one follow-up (varied from 1 to 8 years). Individuals in F+ groups performed worse and dropped faster in Mini-Mental State Examination scale and had faster shrinking middle temporal lobe than those in F- groups (all p < 0.05). Moreover, in MCI patients, reduced FDG-PET exerted 2.47 to 4.08-fold risk of AD dementia progression compared with those without significantly impaired FDG-PET (both p < 0.001). CONCLUSIONS: Based on the analyses, separating FDG-PET from "N" biomarker to build the ATN(F) system is necessary and well-founded. The analysis from this study could be a complement to the original ATN framework for AD's biological definition.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Since CSF collection is invasive, positron emission tomography (PET) and magnetic resonance imaging (MRI) scans are used as noninvasive methods to detect metabolic and structural brain changes associated with AD [221,222,223].”
From The Impact of Neurotoxin Proteins Trafficked by Primary Cilia and Extracellular Vesicles in Neurodegenerative Diseases (2025) · cites this paper as [222]
Experimental — accuracy not yet measuredIn the citing paper
“AD patients exhibit decreased uptake of FDG on PET [220]”
From Genetic architecture of Alzheimer's disease (2020) · cites this paper as [220]
In the citing paper
“PET imaging can also be used to measure glucose metabolism in the brain through the utilization of a radiolabeled alternate form of glucose, 18F-fluorodeoxyglucose (FDG) [220].”
From Genetic architecture of Alzheimer's disease (2020) · cites this paper as [220]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.005 · Cited by 18,657
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123
NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
Jack, C. R., Bennett, D. A., Blennow, K., Carrillo, M. C., Dunn, B., Haeberlein, S. B., Holtzman, D. M., Jagust, W., Jessen, F., Karlawish, J., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.018 · Cited by 10,537
Sperling, R. A., Aisen, P. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, A. M., Iwatsubo, T., Jack, C. R., Kaye, J., Montine, T. J., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.003 · Cited by 7,155
Sokoloff, L., Reivich, M., Kennedy, C., Rosiers, M. H. D., Patlak, C. S., Pettigrew, K. D., Sakurada, O., & Shinohara, M. (1977) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1977.tb10649.x · Cited by 6,000
Current concepts in mild cognitive impairment
Petersen, R. C., Doody, R., Kurz, A., Mohs, R. C., Morris, J. C., Rabins, P. V., Ritchie, K., Rossor, M., Thal, L., & Winblad, B. (2001) · Archives of Neurology · doi:10.1001/archneur.58.12.1985 · Cited by 4,781
Squire, L. R., Stark, C. E. L., & Clark, R. E. (2004) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.27.070203.144130 · Cited by 2,680
Alzheimer's Disease Neuroimaging Initiative (ADNI)
Petersen, R. C., Aisen, P. S., Beckett, L. A., Donohue, M. C., Gamst, A. C., Harvey, D. J., Jack, C. R., Jagust, W. J., Shaw, L. M., Toga, A. W., et al. (2010) · Neurology · doi:10.1212/wnl.0b013e3181cb3e25 · Cited by 2,572
Buckner, R. L., Snyder, A. Z., Shannon, B. J., LaRossa, G., Sachs, R., Fotenos, A. F., Sheline, Y. I., Klunk, W. E., Mathis, C. A., Morris, J. C., et al. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.2177-05.2005 · Cited by 2,140
Jack, C. R., Albert, M. S., Knopman, D. S., McKhann, G. M., Sperling, R. A., Carrillo, M. C., Thies, B., & Phelps, C. H. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.004 · Cited by 2,042
Cited by
EANM procedure guidelines for brain PET imaging using [18F]FDG, version 3
Guedj, E., Varrone, A., Boellaard, R., Albert, N. L., Barthel, H., van Berckel, B., Brendel, M., Cecchin, D., Ekmekcioglu, O., Garibotto, V., et al. (2022) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-021-05603-w · Cited by 300
“A recent study suggests that [18F] FDG-PET is an independent biomarker to predict AD conversion in patients with mild cognitive impairment (MCI) along with amyloid-β and tau, independently of hippocampal volume [12] and of amyloid PET status [13, 14].”
BackgroundHu, H.-Y., Ou, Y.-N., Shen, X.-N., Qu, Y., Ma, Y.-H., Wang, Z.-T., Dong, Q., Tan, L., & Yu, J.-T. (2021) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2020.11.007 · Cited by 279
Self-citationvan Oostveen, W. M., & de Lange, E. C. M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22042110 · Cited by 297
“because, as mentioned before, FDG uptake is likely to reflect the glucose consumption by astrocytes instead of neurons [80,174].”
BackgroundSafiri, S., Ghaffari Jolfayi, A., Fazlollahi, A., Morsali, S., Sarkesh, A., Daei Sorkhabi, A., Golabi, B., Aletaha, R., Motlagh Asghari, K., Hamidi, S., et al. (2024) · Frontiers in Medicine · doi:10.3389/fmed.2024.1474043 · Cited by 200
The Key Role of Mitochondrial Function in Health and Disease
San-Millán, I. (2023) · Antioxidants · doi:10.3390/antiox12040782 · Cited by 218
Metadata
- Authors
- Initiative, O. B. O. A. D. N., Ou, Y.-N., Xu, W., Li, J.-Q., Guo, Y., Cui, M., Chen, K.-L., Huang, Y.-Y., Dong, Q., Tan, L., & Yu, J.-T.
- Affiliations
- Qingdao University (CN)
- Shanghai Medical College of Fudan University (CN)
- Corresponding author
- Yu, Jin-Tai
- Venue
- Alzheimer's Research & Therapy
- Published
- 2019-06-29
- Volume
- 11
- Issue
- 1
- Pages
- 57-57
- ISSN
- 1758-9193 (ISSN-L)
- PMC
- PMC6599313
- OpenAlex
- W2953750178
- Cited by
- 155
- References
- 50
- Citations by year
- 2026: 10 · 2025: 23 · 2024: 25 · 2023: 28 · 2022: 26 · 2021: 26 · 2020: 16 · 2019: 1
- FWCI
- 13.72
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor)
- Locations
- Alzheimer s Research & Therapy (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- U.S. Department of Defense (U01 AG024904, W81XWH, W81XWH-12-2-, W81XWH-12, W81XWH1220012, AG024904)
- Foundation for the National Institutes of Health (W81XWH-12-2-0012, U01AG024904, Grant U01 AG024904, AG024904)
- Alzheimer's Association (U01 AG024904, W81XWH-12-2-0012)
- Bristol-Myers Squibb (U01 AG024904, AG024904, W81XWH-12-2-0012)
- Eli Lilly and Company (U01 AG024904, AG024904, W81XWH-12-2-0012)
- Pfizer (AG024904, W81XWH-12-2-0012, U01 AG024904)
- Biogen (W81XWH-12-2-0012, U01 AG024904, AG024904)
- University of Southern California (W81XWH-12-2-0012, U01 AG024904)
- F. Hoffmann-La Roche (W81XWH-12-2-0012, AG024904, U01 AG024904)
- Meso Scale Diagnostics (U01 AG024904, AG024904, W81XWH-12-2-0012)
- Alzheimer's Disease Neuroimaging Initiative (W81XWH-12-2–0012, U01AG024904, AG024904, W81XWH-12-2-, Department of Defense award number W81XWH-12-2-0012)
- BioClinica (U01 AG024904, W81XWH-12-2-0012, AG024904)
- Novartis Pharmaceuticals Corporation (W81XWH-12-2-0012, U01 AG024904, AG024904)
- Northern California Institute for Research and Education (U01 AG024904, W81XWH-12-2-0012)
- National Natural Science Foundation of China (81771148, 2018YFC1314700, 91849126, U01 AG024904, W81XWH-12-2-0012, 2018SHZDZX01, 81571245)
- Fudan University (2018SHZDZX01)
- Eisai (W81XWH-12-2-0012, U01 AG024904, AG024904)
- Servier (AG024904, W81XWH-12-2-0012, U01 AG024904)
- H. Lundbeck A/S (U01 AG024904, AG024904, W81XWH-12-2-0012)
- IXICO (AG024904, W81XWH-12-2-0012, U01 AG024904)
- National Institutes of Health (3u01ag024904-10s2, W81XWH, W81XWH-12-2-0012, U01-AG024904, Grant U01 AG024904, AG024904)
- Genentech (W81XWH-12-2-0012, AG024904, U01 AG024904)
- Canadian Institutes of Health Research (U01 AG024904, W81XWH-12-2-0012)
- National Institute on Aging (U01-AG-024904, W81XWH-12-2–0012, AG 024904)
- National Institute of Biomedical Imaging and Bioengineering (W81XWH-12-2-0012, U01 AG024904, AG024904)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
- Keywords
- FDG-PET, Alzheimer's disease, biological diagnosis, neurodegeneration biomarkers, brain glucose metabolism, mild cognitive impairment, conversion to dementia, cognitive decline, Alzheimer's Disease Neuroimaging Initiative
- MeSH terms
- Aged, Alzheimer Disease, Brain, Female, Humans, Longitudinal Studies, Male, Biomarkers, Disease Progression, Fluorodeoxyglucose F18, Positron-Emission Tomography, Cognitive Dysfunction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: FDG-PET as an independent biomarker for Alzheimer’s biological diagnosis: a longitudinal study. https://app.cochat.ai/papers/10.1186/s13195-019-0512-1
- The paper
- Initiative, O. B. O. A. D. N., Ou, Y.-N., Xu, W., Li, J.-Q., Guo, Y., Cui, M., Chen, K.-L., Huang, Y.-Y., Dong, Q., Tan, L., & Yu, J.-T. (2019). FDG-PET as an independent biomarker for Alzheimer’s biological diagnosis: a longitudinal study. Alzheimer's Research & Therapy. https://doi.org/10.1186/s13195-019-0512-1
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.